These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18393326)

  • 1. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population.
    Weight CJ; Klein EA; Jones JS
    Cancer; 2008 May; 112(10):2195-201. PubMed ID: 18393326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.
    Chang SL; Liao JC; Shinghal R
    J Urol; 2009 Jul; 182(1):255-60; discussion 261. PubMed ID: 19450844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement policy and androgen-deprivation therapy for prostate cancer.
    Shahinian VB; Kuo YF; Gilbert SM
    N Engl J Med; 2010 Nov; 363(19):1822-32. PubMed ID: 21047226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer.
    Chon JK; Jacobs SC; Naslund MJ
    J Urol; 2000 Sep; 164(3 Pt 1):735-7. PubMed ID: 10953136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does reimbursement influence chemotherapy treatment for cancer patients?
    Jacobson M; O'Malley AJ; Earle CC; Pakes J; Gaccione P; Newhouse JP
    Health Aff (Millwood); 2006; 25(2):437-43. PubMed ID: 16522584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991 to 1993.
    Litwin MS; Pasta DJ; Stoddard ML; Henning JM; Carroll PR
    J Urol; 1998 Aug; 160(2):445-8. PubMed ID: 9679895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
    Mariani AJ; Glover M; Arita S
    J Urol; 2001 Jan; 165(1):104-7. PubMed ID: 11125375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surgical or medical castration with LH-RH analogue for prostatic cancer].
    Kameyama S; Yamazaki S; Kitamura T
    Nihon Rinsho; 1998 Aug; 56(8):2114-8. PubMed ID: 9750518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the increase in orchiectomy for prostate cancer patients appropriate?
    Chodak GW
    Cancer; 2008 May; 112(10):2106-7. PubMed ID: 18386828
    [No Abstract]   [Full Text] [Related]  

  • 10. Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer.
    Garje R; Chennamadhavuni A; Mott SL; Chambers IM; Gellhaus P; Zakharia Y; Brown JA
    Clin Genitourin Cancer; 2020 Apr; 18(2):e157-e166. PubMed ID: 31956009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare in interventional pain management: A critical analysis.
    Manchikanti L
    Pain Physician; 2006 Jul; 9(3):171-97. PubMed ID: 16886027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare reimbursement and prescribing hormone therapy for prostate cancer.
    Keating NL
    J Natl Cancer Inst; 2010 Dec; 102(24):1814-5. PubMed ID: 21131579
    [No Abstract]   [Full Text] [Related]  

  • 14. The fate of the medically castrated testis: expectation versus reality.
    Issa MM; Krishnan A; Bouet R; Young MR; Hood N; Petros JA
    J Urol; 2004 Sep; 172(3):1042-4. PubMed ID: 15311033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica.
    Morrison BF; Aiken WD; Reid ME
    Rev Panam Salud Publica; 2011 Jun; 29(6):404-8. PubMed ID: 21829963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States.
    Cetin K; Li S; Blaes AH; Stryker S; Liede A; Arneson TJ
    Urology; 2013 Jun; 81(6):1184-9. PubMed ID: 23601449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of androgen deprivation therapy: some questions answered, others not.
    Schellhammer PF
    J Natl Cancer Inst; 2006 Jun; 98(12):802-3. PubMed ID: 16788149
    [No Abstract]   [Full Text] [Related]  

  • 18. Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment.
    Ellis SD; Chen RC; Dusetzina SB; Wheeler SB; Jackson GL; Nielsen ME; Carpenter WR; Weinberger M
    J Oncol Pract; 2016 Apr; 12(4):e423-36. PubMed ID: 26957641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.
    Novara G; Galfano A; Secco S; Ficarra V; Artibani W
    Urol Int; 2009; 82(3):249-55. PubMed ID: 19440008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care?
    Friedman JY; Curtis LH; Hammill BG; Dhillon JK; Weaver CH; Biswas S; Abernethy AP; Schulman KA
    Cancer; 2007 Nov; 110(10):2304-12. PubMed ID: 17924373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.